News Center

Home page

Peak Report

News reports

The 14th meeting of the 10th board of directors and the 9th meeting of the 9th board of supervisors were held.

Release time:

2020-07-22

10th 14 Board of Directors, 9th 9 Board of Supervisors Held

to Review and Pass Annual Work Report and Other Related Proposals

News 4 May 24 , jiang Xiaomeng, chairman of the group company, presided over the 14 meeting of the 10th board of directors of the company, and reviewed and approved 14 related reports and proposals such as 2019 board of directors report, 2019 general manager business report, 2019 annual report, etc.

General Manager's report pointed out that 2019 is the first year of the implementation of the Group's new five-year strategic development plan (2019-2023 ) and the new three-year business plan (2019-2021) for each business sector. The management team focuses on the general working policy of "innovation and reform, integration and promotion, scientific layout and steady development, orderly carry out all kinds of operation and management work, and better fulfill the business objectives set by the board of directors at the beginning of the year. In the whole year, the company realized a total operating income of 35.48 .9 billion yuan, up 5.51% year on year. Net profit attributable to shareholders reached 7.25 .3 billion yuan, earnings per share reached 2.11 yuan, up 23.14% year on year, reaching a new record high. At the end of the year, total assets reached 54.75 .9 billion yuan, up 11.71% year on year; net assets attributable to shareholders were 37.89 .3 billion yuan, up 19.81% year on year.

During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, 2019 cement industry operation is generally stable, industry efficiency further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons (with waste heat power generation). During the reporting period, the company completed the construction investment of 4.47 .5 billion yuan, and the project progressed smoothly; yunnan Jianfeng invested ,500 yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., accounting for 10% of its shares, further expanding the company's cement business segment. During the reporting period, Daye Peak and Yunnan Peak continued to carry out in-depth "three reductions and three improvements" activities, steadily implemented standardized management, vigorously introduced advanced and applicable technologies to implement technological transformation, and continuously improved the labor productivity of enterprises while strictly controlling production costs. The leading position of the regional market has been further consolidated and enhanced, 2019 Daye Peak to achieve a net profit of 2.98 .3 billion yuan, Yunnan Peak to achieve a net profit of 2.71 .5 billion yuan, the company's cement sector operating performance hit a new record high.

2019 was a year of constant volatility and accelerated differentiation in the pharmaceutical market, with the introduction of new pharmaceutical policies to promote the development of the entire industry in the direction of concentration, innovation and high quality. During the reporting period, in order to fully cope with the changes in the industry and enrich the company's product line, Jianfeng Pharmaceutical Co., Ltd. further strengthened its product research and development and innovation. More than 81,20 882 research projects were in various stages of preclinical research, clinical research, pre-production research or production application. Olopatadine Hydrochloride Eye Drops obtained the drug registration approval and put it on the market. Paroxetine Hydrochloride Tablets passed the consistency evaluation smoothly, the drug supplementary application approval was obtained in 2020 ; Complete the registration and consistency evaluation declaration of cefmenoxime hydrochloride raw materials and injections; Complete the registration and filing of imatinib mesylate raw materials and tablet registration declaration. 2019 , Jianfeng Pharmaceutical and its subsidiaries made new progress in a number of technological transformation and engineering construction. The construction of the annual production of 20 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical is progressing smoothly. The project is listed as a major industrial project in Zhejiang Province in 2019 and a key technological transformation project in Jinhua City in 2020 ; the implementation of Anhui Beika and Anhui Zhongwang Phase II technological transformation projects will upgrade and on the basis of their existing products to become the company's comprehensive research and development and production base for raw materials, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of peak pharmaceutical raw materials and preparations. On the day of

, the company also held the 9th 100

meeting of the 9th board of supervisors, deliberating and passing 109 related reports and proposals of 2019 annual board of supervisors, 2019 annual financial final accounts report, 2019 annual profit distribution plan and other . (Yu Fruit)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页